SANNO, member of CataloniaBio & HealthTech, has been selected for a groundbreaking program with EIT Health, Takeda, and KU Leuven, focusing on the early detection and better management of inflammatory bowel disease (IBD). This initiative focuses on advancing and validating innovative technologies designed to predict IBD flares.
The SANNO platform collects and analyses patient data to predict patterns in treatment, enabling better understanding of the patient’s progression with data analytics. The platform also drives patient engagement with personalised content to manage health conditions.
IBD management is one of the core pillars of SANNO, which integrates digital and lab biomarkers with actionable data, delivering deeper insights into the disease's trajectory and the effectiveness of treatments.
Ariadna Masó, who started SANNO because of her own journey with a gut condition, is passionate about changing IBD care for the better with cutting-edge technology and insights.
Comments